<DOC>
	<DOCNO>NCT02423889</DOCNO>
	<brief_summary>This prospective , single arm , phase II , multicentric study . It evaluate acute late toxicity stereotactic radiotherapy low risk prostate cancer patient . All participant receive total dose 36.25 Gy 5 fraction , twice week , 7.25 Gy per fraction .</brief_summary>
	<brief_title>Stereotactic Volumetric Radiotherapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histology prostate adenocarcinoma Age≥ 18 year Life expectancy≥ 10 year Clinical negative node ( N0 ) No metastasis presence ( M0 ) No previous pelvic radiation therapy Total PSA≤10 ng/ml Gleason score ≤ 6 T12 ≤ 3 positive biopsy prostatic mapping Signed informed consent Positive node ( N+ ) metastatic disease ( M+ ) Inflammatory bowel disease , collagen vascular disorder active autoimmune disorder Anticoagulant treatment progress Hip pelvic presence medical device could prevent correct image acquisition Symptomatic haemorrhoidal disease Adverse reaction iodinate paramagnetic contrast medium Previous malignant cancer , except basocellular skin tumour tumour heal since 5 year Previous pelvic radiotherapy Psychiatric disorder preclude obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hypofractionated radiotherapy</keyword>
	<keyword>SBRT</keyword>
</DOC>